US Stem Cell Inc (USRM)

[Zues]

Tomas,

"...we feel that our shareholders and patients will be better served if we focus our efforts on therapies that benefit patients RIGHT NOW."

I think they can and should be pursuing both RMAT and revenues now that guidelines will be released in Sept. Because the playing filed is shifting quickly, USRM needs to be nimble like any other opportunistic business. The money they invested into MyoCell was a means to an end, correct?

JMO